WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

Firm News

Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced that two additional pharmaceutical companies, Pfizer Inc. and AbbVie Inc., have invested in their work to treat Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment, that WilmerHale also handled, made by Takeda Pharmaceuticals in December 2015.

The WilmerHale team counseling Aquinnah Pharmaceuticals included Joshua Fox and Stephanie Singer.

Read Aquinnah Pharmaceuticals' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.